Inhibrx Biosciences Inc (INBX) Stock Price, Quote & News

Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lu...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 795 4220

Website: inhibrx.com

Address:

11025 North Torrey Pines Road, Suite 140, La Jolla, United States

MBWallingford Jul. 15 at 1:27 PM

$INBX 20 shares? Some kind of head fake.

0 · Reply

Innerchild Jul. 10 at 8:29 AM

$MTEN Stop buying Mten this shit , go buy rather $JLHL $OMEX $CRMT $INBX Go long for tickers that actually pay, but be careful with JLHL it’s a Chineese / Asian, shit could go sideways, just like GDC.

0 · Reply

MBWallingford Jul. 9 at 11:12 PM

$INBX the stock is now acting like something is brewing. A bit more volume would confirm.

0 · Reply

Stacks_Edwards Jul. 9 at 3:46 PM

$INBX Let’s get going here baby!!

0 · Reply

Mike22332233 Jul. 9 at 3:14 PM

$INBX I Believe $MRK has a strong interest to buy out BOTH OF THESE — $SLS and $INBX — my number one and number two top holdings !!! … Which will go first??? Thoughts … LIKE & FOLLOW @mike22332233

1 · Reply

Doozio Jul. 8 at 12:21 AM

$INBX again this 🐑 week ENTA 🐒🍌🧠⏰♾️?

0 · Reply

Mike22332233 Jul. 7 at 6:43 PM

$SLS Will $MRK do a BO of $SLS or of $INBX FIRST?? … Will they do both??? … I am covered either way … LIKE & FOLLOW me 👉 @Mike22332233 for SLS insight you will find nowhere else

0 · Reply

Innerchild Jul. 7 at 6:20 PM

$MTEN will Soon 🚀🚀🚀 $VRXA $PHOE $INBX all going down now

0 · Reply

Layne_Thomas_Staley Jul. 7 at 6:01 PM

$INBX $

0 · Reply

justiceforb_85 Jul. 6 at 11:04 PM

$INBX look forward to PFS update for 106 in the fall.

0 · Reply

Inhibrx announces FDA acceptance of BLA for ozekibart

Jun 15, 2026, 9:15 AM EDT - 4 weeks ago

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

2026-05-15T13:15:11.000Z - 2 months ago

Inhibrx price target raised to $325 from $300 at Stifel

May 14, 2026, 4:02 PM EDT - 2 months ago

Inhibrx Reports First Quarter 2026 Financial Results

May 14, 2026, 7:00 AM EDT - 2 months ago

Inhibrx Biosciences Quarterly report: Q1 2026

2026-05-11T16:20:41.000Z - 2 months ago

Inhibrx’s INBRX-106 shows potential benefit in HNSCC

May 11, 2026, 8:30 AM EDT - 2 months ago

Inhibrx Biosciences Transcript: Study update

May 11, 2026, 8:30 AM EDT - 2 months ago

Inhibrx Biosciences Press release: Study update

May 11, 2026, 8:26 AM EDT - 2 months ago

This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know.

May 11, 2026, 8:00 AM EDT - 2 months ago

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

May 8, 2026, 4:00 PM EDT - 2 months ago

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

2026-04-24T13:35:38.000Z - 2 months ago

Inhibrx initiated with an Outperform at LifeSci Capital

Apr 23, 2026, 8:00 AM EDT - 3 months ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 3 months ago

Inhibrx Biosciences Proxy statement: Proxy filing

2026-04-22T16:50:17.000Z - 3 months ago

Inhibrx price target raised to $300 from $150 at Stifel

2026-04-22T14:07:06.000Z - 3 months ago

Inhibrx trading halted, volatility trading pause

2026-04-22T14:01:35.000Z - 3 months ago

Inhibrx trading resumes

2026-04-22T12:50:13.000Z - 3 months ago

Inhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says

MRK

2026-04-22T12:49:00.000Z - 3 months ago

Inhibrx up 39% at $117 after report of interest from Merck in cancer assets

Apr 22, 2026, 7:02 AM EDT - 3 months ago

Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

MRK

Apr 21, 2026, 4:30 PM EDT - 3 months ago

Inhibrx Biosciences Transcript: Study update

Apr 21, 2026, 4:30 PM EDT - 3 months ago

Inhibrx Biosciences Press release: Study update

2026-04-21T20:24:03.000Z - 3 months ago

Inhibrx reports interim data from its Phase 1/2 study evaluating ozekibart

Apr 21, 2026, 4:05 PM EDT - 3 months ago

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Apr 21, 2026, 7:00 AM EDT - 3 months ago

Inhibrx Biosciences Slides: Investor presentation

Apr 20, 2026, 5:03 PM EDT - 3 months ago

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

2026-04-07T20:17:46.000Z - 3 months ago

Inhibrx initiated with a Buy at Stifel

Mar 19, 2026, 6:00 PM EDT - 4 months ago

Inhibrx Biosciences Earnings release: Q4 2025

Mar 19, 2026, 6:00 PM EDT - 4 months ago

Inhibrx Biosciences Annual report: Q4 2025

2026-03-19T20:10:58.000Z - 4 months ago

Inhibrx reports Q4 EPS ($2.11) vs. ($3.09) last year

Mar 19, 2026, 4:00 PM EDT - 4 months ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Mar 12, 2026, 7:00 AM EDT - 4 months ago

Inhibrx Biosciences Slides: Investor presentation

Mar 2, 2026, 4:00 PM EST - 4 months ago

Inhibrx Announces Participation in Upcoming Scientific Conference

Jan 22, 2026, 10:26 AM EST - 6 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE KOD LITE

2025-12-16T22:10:33.000Z - 7 months ago

Inhibrx provides update on INBRX-106 Phase 2/3 clinical trial

Dec 16, 2025, 5:00 PM EST - 7 months ago

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Nov 14, 2025, 6:00 AM EST - 8 months ago

Inhibrx Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 6:00 PM EST - 8 months ago

Inhibrx Biosciences Quarterly report: Q3 2025

Nov 13, 2025, 6:00 PM EST - 8 months ago

Inhibrx Biosciences Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 9 months ago

Inhibrx Announces Participation in Upcoming Scientific Conferences

Oct 23, 2025, 6:39 PM EDT - 9 months ago

Inhibrx shares surge after bone cancer drug slows disease progression in trial

Oct 23, 2025, 4:30 PM EDT - 9 months ago

Inhibrx Biosciences Transcript: Study Result

Oct 23, 2025, 4:30 PM EDT - 9 months ago

Inhibrx Biosciences Press release: Study Result

Oct 23, 2025, 4:05 PM EDT - 9 months ago

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Oct 22, 2025, 4:01 PM EDT - 9 months ago

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Aug 13, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 6:00 PM EDT - 1 year ago

Inhibrx Biosciences Quarterly report: Q2 2025

Aug 12, 2025, 6:00 PM EDT - 1 year ago

Inhibrx Biosciences Earnings release: Q2 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports First Quarter 2025 Financial Results

May 14, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Quarterly report: Q1 2025

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 1, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Mar 17, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Inhibrx Biosciences Earnings release: Q4 2024

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Inhibrx Biosciences Annual report: Q4 2024

Jan 21, 2025, 5:01 PM EST - 1 year ago

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Jan 13, 2025, 4:15 PM EST - 1 year ago

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Nov 14, 2024, 4:24 PM EST - 1 year ago

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 7:00 AM EST - 1 year ago

Inhibrx Biosciences Quarterly report: Q3 2024

Nov 4, 2024, 4:00 PM EST - 1 year ago

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Aug 13, 2024, 6:54 PM EDT - 2 years ago

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Quarterly report: Q2 2024

Jun 11, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Registration statement: Registration filing

May 24, 2024, 4:00 PM EDT - 2 years ago

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

May 21, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

May 17, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

May 10, 2024, 6:36 PM EDT - 2 years ago

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

May 9, 2024, 3:36 PM EDT - 2 years ago

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SNY

May 8, 2024, 4:37 PM EDT - 2 years ago

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Feb 29, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Feb 28, 2024, 9:15 AM EST - 2 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 28, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Annual report: Q4 2023

Feb 6, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 11:45 AM EST - 2 years ago

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

SNY

Jan 23, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 5:39 AM EST - 2 years ago

Sanofi to Buy Rare-Disease Assets From Inhibrx

SNY

Jan 23, 2024, 1:32 AM EST - 2 years ago

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

SNY

Jan 23, 2024, 1:30 AM EST - 2 years ago

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

SNY

Jan 23, 2024, 1:00 AM EST - 2 years ago

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

SNY

Nov 9, 2023, 4:00 PM EST - 2 years ago

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Sep 19, 2023, 4:00 PM EDT - 3 years ago

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Sep 1, 2023, 4:26 PM EDT - 3 years ago

Andreas Halvorsen's Firm Ups Inhibrx Stake

Aug 29, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Announces $200 Million Private Placement Financing

Aug 7, 2023, 4:00 PM EDT - 3 years ago

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

May 30, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 8, 2023, 4:05 PM EDT - 3 years ago

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Apr 26, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Apr 13, 2023, 8:00 AM EDT - 3 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Apr 13, 2023, 8:00 AM EDT - 3 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Mar 6, 2023, 4:05 PM EST - 3 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Mar 6, 2023, 7:00 AM EST - 3 years ago

Inhibrx Biosciences Annual report: Q4 2022

Jan 4, 2023, 9:00 AM EST - 3 years ago

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

Nov 18, 2022, 4:05 PM EST - 3 years ago

Inhibrx Announces Participation in Upcoming Investor Conference

MBWallingford Jul. 15 at 1:27 PM

$INBX 20 shares? Some kind of head fake.

0 · Reply

Innerchild Jul. 10 at 8:29 AM

0 · Reply

MBWallingford Jul. 9 at 11:12 PM

$INBX the stock is now acting like something is brewing. A bit more volume would confirm.

0 · Reply

Stacks_Edwards Jul. 9 at 3:46 PM

$INBX Let’s get going here baby!!

0 · Reply

Mike22332233 Jul. 9 at 3:14 PM

1 · Reply

Doozio Jul. 8 at 12:21 AM

$INBX again this 🐑 week ENTA 🐒🍌🧠⏰♾️?

0 · Reply

Mike22332233 Jul. 7 at 6:43 PM

$SLS Will $MRK do a BO of $SLS or of $INBX FIRST?? … Will they do both??? … I am covered either way … LIKE & FOLLOW me 👉 @Mike22332233 for SLS insight you will find nowhere else

0 · Reply

Innerchild Jul. 7 at 6:20 PM

$MTEN will Soon 🚀🚀🚀 $VRXA $PHOE $INBX all going down now

0 · Reply

Layne_Thomas_Staley Jul. 7 at 6:01 PM

$INBX $

0 · Reply

justiceforb_85 Jul. 6 at 11:04 PM

$INBX look forward to PFS update for 106 in the fall.

0 · Reply

Mike22332233 Jul. 2 at 6:04 PM

$KODK The richer I get, the less tolerance I have for "JACKASSES", of which there are too many both $SLS and in $KODK and in $INBX ... my top 3 holdings !!! ... LIKE AND FOLLOW @Mike22332233 for latest info

0 · Reply

MBWallingford Jun. 26 at 8:13 PM

$INBX keep hearing about buyouts but stock is not moving.

1 · Reply

MBWallingford Jun. 23 at 2:10 PM

$INBX no volume.

0 · Reply

History101 Jun. 19 at 6:14 PM

$APGE news is out that $ABBV is buying APGE for a big premium. APGE was one of 3 buyout targets (other 2 were $COGT & $INBX) mentioned by the biotech analyst on CNBC Fast Money last night..

1 · Reply

justiceforb_85 Jun. 19 at 2:20 AM

$INBX the first company to show efficacy via OX40 agonism in a randomized setting. Severely undervalued.

0 · Reply

Innerchild Jun. 18 at 2:47 PM

$GDC Could be the next big run $DGXX $MTEN $INBX

0 · Reply

Woundntyouliketoknow Jun. 16 at 1:28 PM

$INBX Great news yesterday but no real stock movement - If only Inhibrx was a Rocket/Internet Provider/AI company it would be able to loss a ton of money - have no real visability on when it could become profitiable and piss away money and yet have a over 2T market cap and keep going up. - Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

0 · Reply

STACKD0E Jun. 15 at 1:24 PM

$INBX $GSHD $FWDI $ENGN

0 · Reply

Roaring_Capybara Jun. 11 at 2:07 PM

$INBX What the Funk is going on here??? I closed out at $133 and YOU people let it get this low??? OK ..... Just bought 250 shares. Now, lets get it where it belongs ..... $200+++

0 · Reply

DeltaVariant Jun. 5 at 3:53 PM

$INBX Starter. I'm not saying buy zone, but pretty close....Now if the market corrects that 20% everyone is expecting, then yea $68

0 · Reply

Mike22332233 Jun. 5 at 12:41 AM

$INBX $ATER $KODK $PZZA I call the kinds of stocks I uncover and invest in, like $SLS and all the others I listed in the re-post below-- Special Situation Stocks ... They could just as easily be called "wake up stocks", because there is nothing to do but HOLD ON TO THEM until you wake up one morning to great headline news and a massive upward re-pricing adjustment !!! ... FOLLOW me 👉 @Mike22332233 for all my latest Special Situation Stocks for FAST & LARGE GAINS

1 · Reply

Mike22332233 Jun. 3 at 9:45 PM

MY TOP SPECIAL SITUATION STOCK HOLDINGS & EXPECTED % RETURNS ... 1) SLS 1,650%-2,650% 2) $INBX 300%-500% 3) $ATER 100%-300% 4) $KODK 50%-100% 5) $PZZA 57%-63% 6) ZIM 43%-51% 7) WEN 40%-46% 8) MNRO 41%-45% 9) DDI 35%-52% 10) LSTA 50% 11) PRTH 21%

0 · Reply

Market Cap	1.37B
Revenue (ttm)	1.30M
Net Income (ttm)	-140.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,773.85%
Debt to Equity Ratio	-8.32

Volume	208,400
Avg Vol	420,460
Day's Range	N/A - N/A
Shares Out	14.67M
Stochastic %K	14%
Beta	3.41
Analysts	Sell
Price Target	$277.50